secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001104659-25-028803
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio receives NYSE delisting notice, market cap ~$37.9M, equity $9.3M; CFO Fricker departs
--------------------------------------------------------------------------------

- NYSE notice: 30-day avg mkt cap ~$37.9M, equity $9.3M at Dec 31, 2024, both below $50M thresholds.
- Company has 45 days to submit compliance plan; NYSE may grant up to 18-month cure period; symbol gets '.BC' indicator.
- No immediate impact on stock listing, business operations, or SEC reporting obligations.
- Interim CFO William Fricker departs March 27 by mutual agreement; no dispute over accounting.
- CEO Maria Maccecchini assumes interim principal financial officer role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925028803/0001104659-25-028803-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925028803/tm2510633d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-028803

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer